Skip to main content

Table 5 Antinuclear antibody detection during adalimumab treatment

From: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

Treatment Week Number of positive ANA sera (%)
   ANA Anti-dsDNA Anti-ENA
Adalimumab (n = 57) 0 4 (7) 0 (0) 3 (5.2)
  24 9 (16) 2 (3.5) 0
  48 12 (21) 4 (7) 2 (3.5)
   Total   16 (28) 4 (7) 5 (9)
   P   <0.01 <0.05 n.s.
Control RA (n = 55) 0 5 (9) 0 4 (7)
  24 2 (3.5) 0 0
  48 3 (5.2) 0 1 (1.7)
   Total   8 (14.5) 0 (0) 5 (8.7)
   P   n.s.   n.s.
  1. ANA, antinuclear antibodies; anti-dsDNA, anti-double-stranded DNA autoantibodies; ENA, extractable nuclear antigens; n.s., not significant; RA, rheumatoid arthritis.